Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Quizartinib advances overall survival in acute myeloid leukaemia patients

Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA

Quizartinib advances overall survival in acute myeloid leukaemia patients ( Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA )

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory...

Dr Paul Bröckelmann - University of Cologne, Cologne, Germany

$The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )$

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in...

Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )

A novel CAR-T cell therapy targeting BCMA is highly effective for patients with...

Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain

$A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain )$

A single dose of ctx001 shows promising efficacy and safety for TDT and severe...

Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy

A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD ( Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy )

Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute...

Dr Harry Erba - The Duke Cancer Institue, Durham, USA

Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute myeloid leukaemia ( Dr Harry Erba - The Duke Cancer Institue, Durham, USA )

Treatment with decitabine resulted in a similar survival and fewer adverse...

Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany

Treatment with decitabine resulted in a similar survival and fewer adverse events compared with chemo in older patients with AML ( Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany )

Lack of access to new cancer medicines in LMICs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Lack of access to new cancer medicines in LMICs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Adagrasib shows CNS penetration and encouraging intracranial activity for...

Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA

Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC and active, untreated CNS metastases ( Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA )

Spotlight on global cancer control at ASCO 2022

Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM

Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )

ASCO 2022: Head and neck cancer highlights

Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA

ASCO 2022: Head and neck cancer highlights ( Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA )

More from ecancer